Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

CompanyDateActionBrokerageRatingPrice TargetImpact on PriceActions
ATE
Antibe Therapeutics
6/3/2021Reiterated byBrookline Capital ManagementBuyN/A    
Antibe Therapeutics logo
ATBPF
Antibe Therapeutics
6/3/2021Reiterated byBrookline Capital ManagementBuyMedium    
Monopar Therapeutics logo
MNPR
Monopar Therapeutics
5/25/2021Reiterated byBrookline Capital ManagementBuyMedium    
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
3/30/2021Reiterated byBrookline Capital ManagementBuyN/A    
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
3/30/2021Reiterated byBrookline Capital ManagementBuy $16.00High    
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
3/25/2021Reiterated byBrookline Capital ManagementBuyHigh    
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
3/12/2021Initiated byBrookline Capital ManagementBuy $12.00High    
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
3/3/2021Target Raised byBrookline Capital ManagementBuy$7.00 -> $10.00High    
Moderna logo
MRNA
Moderna
2/26/2021Target Raised byBrookline Capital ManagementBuy$180.00 -> $205.00Low    
CNS Pharmaceuticals logo
CNSP
CNS Pharmaceuticals
2/2/2021Initiated byBrookline Capital ManagementBuy $10.00Low    
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
12/17/2020Initiated byBrookline Capital ManagementBuy $21.00High    
Veru logo
VERU
Veru
12/14/2020Target Raised byBrookline Capital Management$13.00 -> $17.00High    
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
11/10/2020Initiated byBrookline Capital ManagementBuy $19.00Low    
CTI BioPharma logo
CTIC
CTI BioPharma
10/23/2020Initiated byBrookline Capital ManagementBuy $7.00Medium    
electroCore logo
ECOR
electroCore
10/23/2020Initiated byBrookline Capital ManagementBuy $5.00Low    
Aspira Women's Health logo
AWH
Aspira Women's Health
10/14/2020Reiterated byBrookline Capital ManagementBuyHigh    
MEI Pharma logo
MEIP
MEI Pharma
10/12/2020Reiterated byBrookline Capital ManagementBuyMedium    
DermTech logo
DMTK
DermTech
9/11/2020Initiated byBrookline Capital ManagementBuyHigh    
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
9/3/2020Initiated byBrookline Capital ManagementBuy $33.00Low    
Medicenna Therapeutics logo
MDNA
Medicenna Therapeutics
8/24/2020Reiterated byBrookline Capital ManagementBuyMedium    
Forte Biosciences logo
FBRX
Forte Biosciences
8/28/2020Initiated byBrookline Capital ManagementBuy $90.00Low    
FSD Pharma logo
HUGE
FSD Pharma
8/20/2020Reiterated byBrookline Capital ManagementBuyLow    
FSD Pharma logo
HUGE
FSD Pharma
8/20/2020Initiated byBrookline Capital ManagementBuy $11.00N/A    
Kura Oncology logo
KURA
Kura Oncology
8/16/2020Reiterated byBrookline Capital ManagementBuyLow    
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
8/18/2020Initiated byBrookline Capital ManagementBuy $5.00High    
Veru logo
VERU
Veru
8/14/2020Reiterated byBrookline Capital ManagementBuyLow    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
8/11/2020Reiterated byBrookline Capital ManagementBuyLow    
ATE
Antibe Therapeutics
7/15/2020Reiterated byBrookline Capital ManagementBuyN/A    
Moderna logo
MRNA
Moderna
7/13/2020Reiterated byBrookline Capital ManagementBuy $95.00High    
Assertio logo
ASRT
Assertio
6/3/2020Initiated byBrookline Capital ManagementBuy $3.50Low    
CohBar logo
CWBR
CohBar
5/27/2020Reiterated byBrookline Capital ManagementBuyMedium    
CohBar logo
CWBR
CohBar
5/28/2020Initiated byBrookline Capital ManagementBuyN/A    
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
5/25/2020Initiated byBrookline Capital ManagementBuy $7.00High    
Cyclacel Pharmaceuticals logo
CYCC
Cyclacel Pharmaceuticals
5/19/2020Initiated byBrookline Capital ManagementBuy $22.00High    
Biocept logo
BIOC
Biocept
5/14/2020Initiated byBrookline Capital ManagementBuyHigh    
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
5/5/2020Initiated byBrookline Capital ManagementBuyHigh    
Daré Bioscience logo
DARE
Daré Bioscience
4/28/2020Initiated byBrookline Capital ManagementBuy $7.50High    
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
4/14/2020Initiated byBrookline Capital ManagementBuy $35.00Low    
EDSA
Edesa Biotech
3/30/2020Initiated byBrookline Capital ManagementBuy $10.00High    
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
3/11/2020Reiterated byBrookline Capital ManagementBuyHigh    
Armata Pharmaceuticals logo
ARMP
Armata Pharmaceuticals
3/13/2020Reiterated byBrookline Capital ManagementBuyHigh    
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
3/12/2020Initiated byBrookline Capital ManagementBuy $15.00N/A    
Monopar Therapeutics logo
MNPR
Monopar Therapeutics
2/19/2020Initiated byBrookline Capital ManagementBuy $42.00High    
BioCardia logo
BCDA
BioCardia
11/26/2019Reiterated byBrookline Capital ManagementBuyLow    
BioCardia logo
BCDA
BioCardia
11/26/2019Initiated byBrookline Capital ManagementBuy $22.00Low    
MDNA
Medicenna Therapeutics
11/19/2019Reiterated byBrookline Capital ManagementBuy C$4.00N/A    
Atreca logo
BCEL
Atreca
8/20/2019Reiterated byBrookline Capital ManagementBuyHigh    
SCYNEXIS logo
SCYX
SCYNEXIS
8/19/2019Reiterated byBrookline Capital ManagementBuyHigh    
Vaxart logo
VXRT
Vaxart
8/15/2019Initiated byBrookline Capital ManagementBuy $6.00Low    
Celsion logo
CLSN
Celsion
7/25/2019Reiterated byBrookline Capital ManagementBuyMedium    
Chiasma logo
CHMA
Chiasma
7/24/2019Reiterated byBrookline Capital ManagementBuyLow    
Veru logo
VERU
Veru
7/29/2019Initiated byBrookline Capital ManagementBuy $12.00High    
Heat Biologics logo
HTBX
Heat Biologics
7/29/2019Initiated byBrookline Capital ManagementBuy$8.00 -> $8.00High    
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
7/29/2019Initiated byBrookline Capital ManagementBuy$6.00 -> $6.00High    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
7/24/2019Reiterated byBrookline Capital ManagementBuyHigh    
Q BioMed logo
QBIO
Q BioMed
5/10/2019Reiterated byBrookline Capital ManagementBuyLow    
Chiasma logo
CHMA
Chiasma
2/6/2019Reiterated byBrookline Capital ManagementBuyLow    
SCYNEXIS logo
SCYX
SCYNEXIS
1/4/2019Reiterated byBrookline Capital ManagementBuyHigh    
Celsion logo
CLSN
Celsion
11/20/2018Reiterated byBrookline Capital ManagementBuyMedium    
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
11/20/2018Reiterated byBrookline Capital ManagementBuyLow    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
9/27/2018Reiterated byBrookline Capital ManagementBuyLow    
Heat Biologics logo
HTBX
Heat Biologics
8/1/2018Reiterated byBrookline Capital ManagementBuyLow    
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
7/27/2018Downgraded byBrookline Capital ManagementBuy -> HoldLow    
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
5/1/2018Reiterated byBrookline Capital ManagementBuyLow    
CSV / Excel Export To export this table to CSV or Excel, upgrade to MarketBeat All Access.

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  17,732 (Vote Outperform)
Underperform Votes:  24,548 (Vote Underperform)
Total Votes:  42,280
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.